Analysts rate Tonix Pharmaceuticals Holdings Corp. (TNXP:NSD) with a Strong Buy rating and a $0.60 target

Based on the Tonix Pharmaceuticals stock forecast from 1 analyst, the average analyst TNXP stock price target is USD 0.60 over the next 12 months. Tonix Pharmaceuticals Holding Corp’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of TNXP stock forecast is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Tonix Pharmaceuticals stock price was USD 0.55Tonix Pharmaceuticals stock price has changed by -0.24% over the past week, -0.65% over the past month and -97.17% over the last year.

 

About Tonix Pharmaceuticals Holdings Corp. (TNXP:NSD):

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

 

Most Recent Analyst Ratings for TNXP’s stock:

Initiated by Noble Capital Outperform USD 0.6 2022-04-18
Target Lowered by Alliance Global Partners Buy USD 4 » USD 2 2021-08-11
Reiterated by Alliance Global Partners Buy USD 3 » USD 4 2021-02-25
Target Raised by Alliance Global Partners USD 2.5 » USD 3 2020-08-20
Upgrades Roth Capital Neutral » Buy USD 4 2019-04-18
Reiterates B. Riley Buy » Neutral USD 8 2018-07-27
Reiterates Roth Capital Buy » Neutral USD 6 » USD 1 2018-07-27
Initiates Coverage On B. Riley Buy USD 8 2018-06-06
Reiterates Dawson James Buy USD 9 2017-08-23
Upgrades Roth Capital Neutral » Buy USD 6 2017-08-18
Reiterate Oppenheimer Holdings Outperform USD 18 » USD 10 2016-02-17
Upgrade Janney Capital Fair Value USD 10 » USD 12 2015-06-29
Initiate Oppenheimer Holdings Outperform USD 18 2015-06-12
Initiate Janney Capital Buy USD 10 2015-05-07
Assigns Roth Capital Buy USD 18.5 2014-01-10
Initiate Roth Capital Buy USD 8.5 2013-10-02
Initiate Dawson James Buy USD 4 2012-04-26

 

 

What we like:

Underpriced compared to earnings:

TNXP stock price is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value:

TNXP stock price is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow:

Tonix Pharmaceuticals had positive total free cash flow in the most recent four quarters.

 

What we don’t like:

Low market capitalization:

TNXP stock is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns:

Tonix Pharmaceuticals is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns, the returns are unpredictable. Proceed with caution.

High volatility:

The total returns for TNXP stock are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns:

The average income yield of TNXP stock over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow:

Tonix Pharmaceuticals had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis:

TNXP stock price is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.